Solara Q1 FY27: Revenue up 20%, PAT up 55% YoY; net debt down 22%

Mgmt Guided Margin ImprovementCfo Debt Reduction RoadmapMgmt Evaded Key QuestionInvestor Communications View source PDF Explain this filing

SOLARA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.1%1-day move

₹507.95

prior close

₹503.50

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.0-0.1+0.0-0.4+0.1+1.4+1.9+2.4+1.2-1.0+8.1+24.4——

Up moveDown movePending

AI summary

Solara posted strong Q1 FY27 results. Revenue at INR384 crore rose 20% year-on-year, EBITDA at INR63.5 crore up 10%, and PAT at INR16.3 crore up 55%, the highest in 18 quarters. Base business revenue climbed 24% to INR307 crore. Ibuprofen business remained weak with negative 12% EBITDA margin. Net debt reduced by about INR135 crore or 22% to INR479 crore; CFO targets net debt free status by FY29. West Asia crisis continues to pressure raw material costs. Management guides for 10% base business growth and 25% plus or minus 1% EBITDA margin. Ibuprofen strategic review due by H1 FY27.

Likely market impact

Strong turnaround momentum with margin expansion and sharp debt reduction, though ibuprofen losses and West Asia raw material risks persist.